January 18, 2022 -- Prellis Biologics has entered into a multitarget drug discovery collaboration and licensing agreement with Bristol Myers Squibb using Prellis Biologics' externalized human immune system (EXIS) based on human lymph node organoids.
EXIS is a synthetic, animal-free, functional human immune system that Prellis developed to harness human immune responses for the development of antibody therapeutics, disease models, and target discovery. The technology is able to accurately match and rapidly replicate human organ and tissue structures, according to the company.
Microscopy image of a lymph node organoid used to recapture human immune responses in vitro. Image courtesy of Prellis Biologics.
Prellis and Bristol Myers Squibb will collaborate on the generation of human antibody libraries for select targets. Prellis will receive an undisclosed upfront payment from Bristol Myers Squibb, as well as funding for R&D activities, plus sales milestones and royalties for licensed antibodies.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
